Beta Thalassaemia
Conditions
Keywords
Beta Thalassaemia, previously GSK2696277, Lentiviral vector, TIGET-BTHAL, Gene therapy
Brief summary
OTL-300 is a gene therapy drug product consisting of autologous hematopoietic stem/progenitor cluster of differentiation (CD) 34+ cells genetically modified with a lentiviral vector (GLOBE) encoding the human beta globin gene. The TIGET-BTHAL is a phase I/II study evaluating safety and efficacy of OTL-300 in subjects with transfusion dependent beta-thalassemia for two years post gene-therapy. Subjects with rare disease who have undergone gene therapy are followed for efficacy and possible delayed adverse events. Thus, this study is designed to follow patients who have received gene therapy on TIGET-BTHAL for an additional six years (for a total of eight years).
Interventions
Safety and efficacy assessment of OTL-300 in subjects with transfusion dependent beta-thalassemia will be performed.
Sponsors
Telethon Institute for Gene Therapy (OSR-TIGET)
IRCCS San Raffaele
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Masking description
No study treatment will be administered.
Intervention model description
No study treatment will be administered in this study. Subjects who have received treatment with OTL-300 in and completed study TIGET-BTHAL will be included in this study.
Eligibility
Sex/Gender
ALL
Age
3 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects who have completed study TIGET-BTHAL i.e. who have received treatment and been followed for two years post treatment with OTL-300. * For adults; capable of giving signed informed consent. For children; informed assent and/or consent in writing signed by the subject and/or parent(s) / legal representative (according to local regulations and age of the subject).
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with absence of abnormal clonal proliferation (ACP) | Up to 6 years | Clonal proliferation describes the selection and reproduction of only one type of cell. |
| Number of subjects with Polyclonal engraftment | Up to 6 years | Integration site analysis will be performed on different hematopoietic lineages from peripheral blood and/or bone marrow. Polyclonality of hematopoiesis is defined as \>1000 unique integration sites retrieved at specified time points. The number of subjects with polyclonality of hematopoiesis will be estimated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with reduction in transfusion rate up to transfusion independence | Up to 6 years | — |
| Number of subjects with transfusion independence | Up to 6 years | Transfusion independence is defined as \<= 1 transfusion in the previous 6 months. |
| Hemoglobin (Hb) levels in subjects achieving transfusion independence | Up to 6 years | — |
| Number of subjects with sustained engraftment of genetically corrected cells | Up to 6 years | Engraftment will be assessed by vector-specific quantitative polymerase chain reaction (PCR) on bone marrow. Sustained engraftment is defined as \>=0.15 vector copy number (VCN)/genome in bone marrow erythroid cells. |
| Number of subjects with overall survival | Up to 6 years | The number of subjects alive over all the trial. |
| Number of subjects with adverse events (AEs), serious AEs (SAEs) | Up to 6 years | — |
| Clinical chemistry laboratory parameters as a measure of safety | Up to 6 years | — |
| Hematology laboratory parameters as a measure of safety | Up to 6 years | — |
| Occurrence of viral infections as a measure of safety | Up to 6 years | Microbiological laboratory tests will be performed to analyze the presence of hepatitis C virus ribonucleic acid (RNA), hepatitis B virus RNA, hepatitis B surface antigen, human T cell lymphotropic virus type 1-2 antibodies. Molecular tests will be performed for human immunodeficiency virus in peripheral blood or plasma. |
| Urinalysis as a measure of safety | Up to 6 years | — |
| Functional assessment of cancer therapy-bone marrow transplant (FACT-BMT) scores | Up to 6 years | — |
| Short-Form-36 (SF-36) scores | Up to 6 years | Impact of disease on overall QoL in adults will be measured using the SF-36. |
| Pediatric Quality of Life (PedsQL) questionnaire scores | Up to 6 years | The PedsQL 4.0 generic core scale will be used to measure QoL in pediatric subjects. |
| Evaluation of growth in pediatric subjects | Up to 6 years | Growth will be assessed by changes in height versus national growth charts and predicted genetic height. |
| Assessment of hormonal levels in pediatric subjects | Up to 6 years | — |
| Changes in puberty status as assessed by clinical examination | Up to 6 years | — |
| Changes in puberty status as assessed by Tanner scale (TS) | Up to 6 years | Puberty will be assessed using TS. |
| Changes in puberty status as assessed by general questioning | Up to 6 years | — |
| Screening for occurrence of antibodies against viruses and toxoplasma as a measure of safety | Up to 6 years | Immunological laboratory tests will be performed to analyze antibodies to Epstein-Barr virus, cytomegalovirus, herpes simplex virus 1-2, varicella zoster virus, toxoplasma. |
| Number of subjects with reduction in red blood cells (RBC) transfusion volume | Up to 6 years | — |
Countries
Italy
Outcome results
None listed